GLP-1 medications like Ozempic and Wegovy have quickly moved from niche treatments to the center of high-stakes conversations across payers about cost, access, and coverage. In this episode, Coral Partner Alison Falb talks with Laura Rudder Huff, Vice President at Gallagher Research & Insights, about how the rise of GLP-1s is shaping employer benefit strategies, equity considerations, and policy debates.